期刊档案

Oncology Advances

ISSN 2996-3427 · Xia & He Publishing Inc. · USA · Quarterly · 创刊 2023

Oncology Advances 完全开放获取,APC 约 680 美元,出版商公布首次决定约 33 天,录用比例约 63%(社区反馈),2025 年发文 20 篇。

影响因子—暂无公布值
中科院分区—未被分区表收录
CiteScore 分区—暂无 CiteScore 排名
审稿周期33 天出版商公布的投稿到首次决定时间(含直接拒稿)
版面费680 USD完全开放获取
录用比例63%投稿社区平均反馈
年发文量20 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Oncology Advances 由 Xia & He Publishing Inc. 出版。按 OpenAlex 近年发文统计,该刊主要发表 Cancer Immunotherapy and Biomarkers、Nanoparticle-Based Drug Delivery、Immunotherapy and Immune Responses 等主题的论文,这 3 个主题约占 28%。(根据 OpenAlex 主题统计与中科院分区数据生成)

Oncology Advances is dedicated to improving the diagnosis and treatment of human malignancies, advancing the understanding of molecular mechanisms underlying oncogenesis, and promoting translation from bench to bedside of oncological sciences. The aim of Oncology Advances is to publish peer-reviewed, high-quality articles in all aspects of translational and clinical studies on human cancers, as well as cutting-edge preclinical and clinical research of novel cancer therapies.

摘自期刊官网 Aims & Scope

主编 Ruiwen Zhang出版商官网

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Cancer Immunotherapy and BiomarkersMedicine16%
  2. Nanoparticle-Based Drug DeliveryMaterials Science6.7%
  3. Immunotherapy and Immune ResponsesImmunology and Microbiology5.3%
  4. Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.3%
  5. Prostate Cancer Diagnosis and TreatmentMedicine4%
  6. Glioma Diagnosis and TreatmentMedicine4%
  7. Cervical Cancer and HPV ResearchMedicine4%
  8. Acute Myeloid Leukemia ResearchMedicine4%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)未收录

该期刊未被此版本分区表收录。

《新锐期刊分区表》( 2026年3月发布)未收录

该期刊未被此版本分区表收录。

期刊分区表( 2023年12月旧的升级版)未收录

该期刊未被此版本分区表收录。

数据库收录

收录数据库:暂无记录。

国际期刊预警名单:各版本均未列入LetPub

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

h-index
3OpenAlex ·
i10-index
0OpenAlex ·
两年平均被引
0.76OpenAlex ·
Gold OA 文章占比
0%LetPub ·

逐年发文量 OpenAlex 统计 · 累计 62 篇 · 当年数据不完整

年份发文量其中 OA被引
20269933
2025202016
202426263
2023770

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

平均审稿速度(社区反馈)
期刊官网数据:平均Median time from submission to first decision: 37 days ; Median time from acceptance to online publishing: 17 days网友分享经验:LetPub ·
平均录用比例(社区反馈)
63%LetPub ·
录用率(出版商公布)
59%出版商官网 ·
投稿到首次决定
33 天出版商官网 ·
评审方式
单盲同行评审出版商官网

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取LetPub

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
出版商官网USD 680 / USD 450——

其他费用与减免(作者指南)

投稿费
无投稿费

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

投稿准备要点2 项,摘自作者指南
参考文献格式
Vancouver 格式
推荐审稿人
可选
出版商官网 · 模型提取,逐项与原文核对
接收的文章类型13 种,含篇幅限制
  1. case reportScope: Case Report manuscripts should describe an individual patient or series of patients (normally less than three) that presented with an unexpected or rare …未说明篇幅
  2. commentaryPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…未说明篇幅
  3. editorialPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…正文 ≤ 1,000 词 · 图表 ≤ 1 · 参考文献 ≤ 10
  4. letterPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…正文 ≤ 1,500 词
  5. letter to the editorPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…正文 ≤ 800 词 · 图表 ≤ 1 · 参考文献 ≤ 10
  6. meta-analysisPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…未说明篇幅
  7. mini-reviewMini-review Unstructured; No more than 250 words ~ 2 ~ 3000 words; Structured as Introduction, main body, and Conclusions ~ 70未说明篇幅
  8. opinionPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…正文 ≤ 1,500 词
  9. original articleScope: Original research manuscripts should describe experimental and/or clinical studies in oncological sciences and clinical oncology, including exploratory a…正文 ≤ 5,000 词 · 图表 ≤ 8 · 参考文献 ≤ 50
  10. research letterResearch Letter ~ 3 ~ 1500 words; Unstructured ~ 20未说明篇幅
  11. reviewPlease ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and t…正文 ≤ 3,000 词 · 图表 ≤ 10 · 参考文献 ≤ 300
  12. systematic reviewScope: A systematic review paper, as defined by the Cochrane Collaboration, is a review of a clearly formulated question that uses explicit, systematic methods …正文 ≤ 5,000 词 · 图表 ≤ 8 · 参考文献 ≤ 70
  13. systematic review and meta-analysisSystematic Review and Meta-analysis Structured with Background and objectives, Methods, Results, and Conclusions; No more than 250 words ~ 8 ~ 5000 words; Struc…未说明篇幅
出版商官网
官网政策摘录AI 使用、作者资格、利益冲突、数据可用性、出版伦理、许可与版权、开放获取、同行评审、查重、预印本、自存档、试验注册 / 报告规范
AI 使用 Use of AI Tools by Reviewers

该期刊规定,审稿中的稿件属于保密内容,审稿人不得将未发表的稿件、图表、补充文件、审稿报告或任何与稿件相关的保密信息上传至公共人工智能平台。 模型中文摘要

Manuscripts under review are confidential. Reviewers must not upload unpublished manuscripts, figures, tables, supplementary files, review reports, or any confidential manuscript-related information to public AI platforms.

原文 ↗出版商官网 ·
作者资格 Author Contributions

该期刊要求在作者姓名、单位及通讯作者信息之后以段落形式提供作者贡献,并按姓名(以缩写标注)列出每位作者的具体参与方式,可计入作者身份的贡献包括研究设计、实验实施、数据分析与解释、稿件撰写、批判性修改、统计分析、经费支持、行政支持以及技术或材料支持。 模型中文摘要

The Authors’ Contributions should be provided in paragraph form following the authors’ names and affiliations and corresponding author(s)’ information. The manner in which each author was involved with the study or preparation of the manuscript is listed with the author’s name (shown as initials, within parentheses). Contributions that are acceptable for inclusion as an author are: study design, p…

原文 ↗出版商官网 ·
利益冲突 Conflict of Interest

该期刊要求所有作者填写ICMJE统一利益冲突披露表,每位作者应通过该表披露任何潜在利益冲突,并对所提供信息的准确性和完整性负责。 模型中文摘要

All authors must check the ICMJE’s unified disclosure form. Each author should check the form to disclose any potential conflict of interest and is responsible for the accuracy and completeness of the provided information. The ICMJE’s form could be downloaded here.

原文 ↗出版商官网 ·
数据可用性 Data Sharing Statement

该期刊要求研究类文章提供数据共享声明,以便读者了解如何获取共享数据,并给出了数据存入知识库、包含在文章内或包含在补充信息文件中等多种示例表述。 模型中文摘要

A Data Sharing Statement is required for research articles through which readers will know how to access the shared data. Sample wording: The [TYPE, such as technical appendix, statistical code, or dataset] data used to support the findings of this study have been deposited in the [NAME] repository ([DOI or other persistent identifier]); The [TYPE] data used to support the findings of this study a…

原文 ↗出版商官网 ·
出版伦理

该期刊要求投稿稿件符合国际出版伦理委员会(COPE)和国际医学期刊编辑委员会(ICMJE)的伦理建议以及一般文章要求。 模型中文摘要

Please ensure that any manuscript you submit to Oncology Advances conforms to the recommendations for ethics of the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE), as well as the general article requirements.

原文 ↗出版商官网 ·
许可与版权 Copyright

该期刊规定已发表文章的版权由作者保留(除非另有说明),作者授予期刊以印刷、出版、销售及其他商业利用等方式发表、复制、展示和存储已发表文章的独家全球权利。 模型中文摘要

The copyright on all published articles will be retained with the authors unless stated otherwise. Authors grant Oncology Advances the sole, worldwide, and exclusive right to publish (i.e., print, publish, sell, and otherwise commercially exploit), reproduce, display, and store the published articles.

原文 ↗出版商官网 ·
开放获取 Open Access

该期刊采用开放获取出版模式,所有文章均按CC BY-NC 4.0许可条款发布,任何人可在正确引用原文的前提下为非商业目的复制、分发或重用这些文章,开放获取期刊的投稿同样接受严格的同行评审和质量控制。 模型中文摘要

Oncology Advances adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are su…

原文 ↗出版商官网 ·
同行评审 Peer Review & Editorial Process

该期刊对所有来稿实行单盲同行评审,即作者不知道审稿人身份而审稿人知道作者身份,同行评审旨在确保研究目标、数据和结论的完整性与透明度。 模型中文摘要

The objective of the peer review process is to ensure the integrity and transparency of the research objectives, data, and conclusions.Editorial ProcessAll articles, solicited and unsolicited, that are submitted to Oncology Advances will be subject to the following single blind peer review process, meaning that the author does not know the identity of the reviewer, but the reviewer knows the ident…

原文 ↗出版商官网 ·
查重 Types of Plagiarism

该期刊将剽窃定义为未恰当引用或注明原始来源而使用已发表文献中的信息(包括文字描述、图表和数据),所有投稿稿件都将通过Crossref Similarity Check剽窃检测软件进行检测。 模型中文摘要

Plagiarism is defined by the Oncology Advances as the use of information, including textual descriptions, figures/tables and data, from a previously published document without proper citation or reference to the original source. All submitted manuscripts will be checked using plagiarism detection software (Crossref Similarity Check).

原文 ↗出版商官网 ·
预印本 Preprint version

该期刊说明预印本是同行评审前的文章版本,不要求作者在投稿前从非营利预印本服务器上删除预印本,并建议在文章被接收后在首页加入接收致谢。 模型中文摘要

A preprint is the version of an article before peer-review. Authors are not requested to remove a preprint from a not-for-profit preprint server before submission. Upon acceptance, we recommend including an acknowledgement of acceptance on the first page, as follows:

原文 ↗出版商官网 ·
自存档 Self-archiving Policy

该期刊允许作者自行存档已发表文章的预印本版本,且可不受禁载期限制地自行存档后印本和已发表版本。 模型中文摘要

Authors of articles published in Oncology Advances are permitted to self-archive the preprint version of the article at any time, and may self-archive the postprint and published version without embargo.

原文 ↗出版商官网 ·
试验注册 / 报告规范 Study Reporting Guidelines

该期刊要求所有研究者按照相应的EQUATOR研究报告指南撰写文章,原创文章、系统综述、荟萃分析、病例报告和研究方案的投稿须附上相应检查清单,并在投稿时注明所遵循的指南。 模型中文摘要

To enhance the quality and transparency of health research, Oncology Advances requires all investigators to prepare articles according to appropriate EQUATOR research reporting guidelines. Each submission of an original article/systematic review/meta-analysis/case report/study protocol should be accompanied by an appropriate checklist as listed below. Authors can find more guidelines at EQUATOR an…

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Xia & He Publishing Inc.
出版国家或地区
USA
出版语言
English
出版周期
Quarterly
创刊年份
2023
ISSN
2996-3427
官方链接

常见问题

关于 Oncology Advances 的常见问题

Oncology Advances 的审稿周期多长?

出版商公布的投稿到首次决定时间约为 33 天(首次决定含直接拒稿),平均录用比例反馈为“63%”;期刊官网公布的录用率为 59%。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Oncology Advances 的投稿格式要求是什么?

据期刊作者指南:参考文献格式:Vancouver 格式;推荐审稿人:可选。以上由模型从作者指南提取并逐项与原文核对,投稿前请以官网最新版本为准。

Oncology Advances 是开放获取期刊吗?版面费多少?

Oncology Advances 为完全开放获取。APC 约 680 美元。

来源与更新

本页事实来自 LetPub、出版商官网、OpenAlex;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-26 归档)。最近更新:。